We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $18.5 · 2 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Fulgent Genetics (FLGT) Presents Promising Data on Head and Neck Cancer Treatment - GuruFocus
Fulgent Genetics (FLGT) Presents Promising Data on Head and Neck Cancer Treatment GuruFocus
Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulgent Genetics COO Jian Xie sells $21,137 in company stock By Investing.com - Investing.com Nigeria
Fulgent Genetics COO Jian Xie sells $21,137 in company stock By Investing.com Investing.com Nigeria
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding Stock Titan
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity - Stock Titan
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity Stock Titan
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 31. | After market close (AMC) | $-0.44 | — | — | $91.77M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | — | — | — | $73.46M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | — | — | — | $207.26M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | — | — | — | $135.51M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 06. | Piper Sandler | — | Maintain | Neutral → Neutral | — | Piper Sandler: Neutral |
| 2025. 11. 12. | Piper Sandler | — | Maintain | Neutral → Neutral | — | Piper Sandler: Neutral |
| 2025. 08. 05. | UBS | — | Upgrade | Neutral → Buy | — | UBS: Neutral → Buy |
| 2025. 08. 05. | Piper Sandler | — | Maintain | Neutral → Neutral | — | Piper Sandler: Neutral |
| 2025. 05. 07. | Piper Sandler | — | Maintain | Neutral → Neutral | — | Piper Sandler: Neutral |
| 2025. 05. 05. | Raymond James | — | Maintain | Outperform → Outperform | — | Raymond James: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 297,355 | $7.81B | 0.01% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 236,954 | $6.22B | 0.01% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 322,189 | $5.12B | 0.00% | — | New position |